Somewhere upstream of that silence sits a question most of us did not ask early enough: who, exactly, was the medical advisor who signed off on the original development strategy, and what had they actually done, in industry, before they sat across from our patients?
That question is the heart of independent medical advisory evaluation in biopharma. It is not, despite what many consultants and recruiters will tell you, a question of credentials alone. The presence of a fellowship, an academic appointment, or even a publication record in a high-impact journal tells us very little about whether someone can shepherd an early-stage clinical asset through the unglamorous work of regulatory interactions, data safety monitoring, and the daily conversations with sites and principal investigators that ultimately determine whether patients stay enrolled, whether endpoints get measured correctly, and whether the trial reaches a meaningful answer at all.
The gap between academic prestige and operational competence in pharmaceutical medicine is something we have watched cost programmes months, sometimes years, and occasionally the entire trajectory of an asset. So we owe our industry, and the patients waiting on the outcomes, a more disciplined approach to vetting.
The Professional Standard: Beyond Academic KOL Status
We begin, as we should, with the question of what makes someone a pharmaceutical physician rather than a clinical academic who occasionally consults. The distinction matters because pharmaceutical medicine is its own specialty, with its own regulatory grammar and its own accountability to patients whose lived experience of a trial is qualitatively different from the lecture-hall understanding most KOLs carry into advisory conversations.
In the United Kingdom, the Faculty of Pharmaceutical Medicine — founded on 29 October 1989 — represents the professional home for physicians working across drug discovery, development, regulation, and safety monitoring. FPM holds a position of considerable weight as the dedicated faculty of the three Royal Colleges of Physicians of the UK, and its membership of roughly 1,600 physicians across 39 countries reflects the international reach of the discipline. Membership signals alignment with a specific standard of practice: pharmaceutical physicians understand the architecture of a clinical development plan, the discipline of a Development Safety Update Report, and the choreography of a regulatory interaction in a way that even the most brilliant academic clinician, working solely within a university hospital, may not.
A fellowship in a learned society tells us what someone knows. A track record in pharmaceutical medicine tells us what they have actually done with that knowledge, under the pressure of timelines and patient outcomes.
For those who have undertaken formal specialty training, completion of Pharmaceutical Medicine Specialty Training provides a route to GMC specialist registration in pharmaceutical medicine. That credential is not a vanity marker; it represents assessed competence across the domains that matter most when an advisory seat is being filled. We tend to look for it first, not because it guarantees excellence, but because it demonstrates that someone has been examined against a national framework specifically designed for the work we need them to do.
And yet — and we say this with care, because many of our colleagues hold these credentials and do extraordinary work — a credential is not a competency. It is the floor, not the ceiling. The harder part of vetting begins after the certificates are in order.
Validating Clinical and Regulatory Competency
When we sit down to evaluate an independent medical advisor, the conversation almost always turns, sooner or later, to a small number of questions that reveal more than any CV. We ask about specific assets the advisor has helped move through pivotal trials. We ask about regulatory interactions they have personally led or substantively contributed to. We ask, in plain language, what they would do differently if they were advising the same asset again.
These are not polite interview questions. They are diagnostic. The advisor who has actually carried an asset through, say, a Scientific Advice procedure with the EMA, or a Type B meeting with the FDA, will answer with a specificity that the academic advisor — even a very accomplished one — will struggle to match. They will know what the agency actually cared about. They will know where the briefing book fell short. They will know what a particular regulator's unspoken concern was, and how they addressed it. These are the textures of pharmaceutical medicine, and they are learned only in the work itself.
We find it useful, in our own practice, to think about competency across three concentric layers.
| Layer | What it covers | How we test for it |
|---|---|---|
| Clinical foundation | Therapeutic area expertise, hands-on patient care, evidence interpretation | Case-based discussion; review of their role in past readouts |
| Regulatory fluency | Direct experience with agency interactions, IND/CTA submissions, scientific advice | Specific examples; named procedures where the advisor can speak in detail |
| Development operations | Trial design, protocol authorship, DSMB and IDMC participation, endpoint selection | Walkthrough of a real protocol they shaped; reflection on what they would change |
The third layer is the one most often underestimated by boards that hire on the strength of a therapeutic reputation alone. Endpoint selection, in particular, is where clinical insight and regulatory discipline meet, and where patient burden most directly shapes whether a trial succeeds. We have seen programmes where an advisor's preference for a biomarker endpoint — intellectually defensible, scientifically elegant — produced a trial that patients found harder to participate in than the protocol designers anticipated. Enrollment lagged. Sites struggled. The endpoint, when it arrived, was harder to interpret than a more conventional measure would have been. None of this was foreseeable from the advisor's publication list. All of it became apparent in the lived experience of the trial itself.
Operational Due Diligence: Assessing Real-World Biopharma Experience
This brings us to the harder half of vetting: operational due diligence, the part of the conversation where we ask the advisor — and ourselves — whether they have actually done the work.
The life sciences due diligence consultancy Alacrita has conducted more than 375 assignments since 2009, and the pattern that emerges from a practice of that scale is instructive. Effective due diligence depends on consultants who have carried internal biopharma responsibility themselves. The person who sat on the inside of a development programme, who felt the pressure of a fiscal year deadline for an IND, who watched a Phase III recruitment curve flatten and had to decide what to do about it — that person evaluates an asset differently from someone whose exposure has been largely external.
Operational due diligence asks not what an advisor knows about an asset, but what they have done with assets when no one was watching them do it.
For early-stage programmes in particular, we look for evidence of direct experience with the regulatory positioning of an asset before it has a clinical proof of concept, with the quality systems it will need to scale, and with CMC readiness as it relates to the clinical plan. These are unglamorous domains, and they are precisely where independent advisors most often disappoint boards that hired them for their therapeutic charisma.
A practical exercise that has served us well: ask the candidate to walk through a real asset evaluation they have led, from first contact to final recommendation. Listen less for the conclusion than for the texture of the thinking. Did they actually interrogate the CMC package, or did they take the data sheet at face value? Did they form their own view on regulatory risk, or did they defer to the sponsor's framing? Did they ask about patient-reported outcomes, and did they know what to do with the answers? The advisor who has done the work will volunteer details. The advisor who has read about the work will speak in generalities.
Structuring Fractional CMO and Advisory Engagements
Credentials and track records matter, but so does the architecture of the engagement itself. We have learned, sometimes the hard way, that the right advisor in the wrong structural arrangement is barely better than the wrong advisor at all.
The fractional Chief Medical Officer model — which has become increasingly common in early-stage biotech and healthcare organisations — typically involves part-time support, often structured around one to two days per week, with minimum commitment periods that usually start at six months. That minimum is not arbitrary. A medical leader who is on board for less than half a year cannot meaningfully integrate into the development programme, the regulatory dialogue, or — crucially — the relationships with investigators and sites that determine whether a trial recruits at all.
When we structure these engagements, we have found three considerations make the difference between an arrangement that compounds value and one that merely fills a seat:
- Define the decision points where the advisor has authority, and the points where they advise but the team decides. Ambiguity here creates more friction than disagreement ever does.
- Build in structured handover moments. A fractional CMO who never hands anything over is a fractional CMO who has not been integrated into the team's working memory.
- Specify the patient-facing dimensions of the role explicitly. If the advisor is involved in protocol design, are they accountable for the patient experience of the protocol? If not, who is?
The third point tends to be the one boards most often leave to chance, and it is the one where we have seen the most preventable harm. A protocol that is internally consistent and statistically defensible can still impose a patient burden that no one on the team has consciously chosen, because no one on the team was specifically accountable for it. The medical advisor's role is, among other things, to be that conscience.
Mitigating Risk in Multidisciplinary Asset Evaluation
Finally, a word on the discipline of multidisciplinary evaluation itself. The independent medical reviewer sits at the intersection of clinical, regulatory, CMC, and commercial considerations, and the value they add depends on their ability to hold those domains in view simultaneously without subordinating any of them.
Multidisciplinary due diligence in biopharma typically evaluates assets across early-stage, pre-clinical, clinical, registration, and market phases, with attention to regulatory positioning, quality systems, CMC readiness, and clinical trial oversight. Each of these domains has its own specialists, and the medical advisor's role is not to replace them but to integrate them — to ask, when the regulatory team recommends one path and the CMC team flags a constraint, what the patient implications are of the combined recommendation.
This is where the difference between an academic KOL and an experienced pharmaceutical physician most clearly shows. The KOL tends to evaluate an asset within the frame of therapeutic possibility. The pharmaceutical physician evaluates it within the frame of therapeutic possibility as constrained by the realities of clinical operations, regulatory dialogue, and patient experience. Both frames are legitimate. Only one of them produces an actionable recommendation.
It is also worth being honest about the limits of any individual advisor. Even the most accomplished pharmaceutical physician cannot be expected to be expert across every therapeutic area, every modality, and every regulatory jurisdiction. We have learned to ask candidates directly about the boundaries of their competence, and we have learned to value the advisors who answer that question with precision rather than reassurance. The advisor who claims fluency in everything is, in our experience, the advisor most likely to fail at something important.
A Closing Reflection
What we are really evaluating, when we evaluate an independent medical advisor, is whether they understand that pharmaceutical medicine is, at its core, an act of stewardship. The asset under development will, if it reaches the people it is meant to reach, become part of someone's care pathway. The endpoint we choose will become, in a real and consequential sense, a measure of someone's outcome. The protocol we design will shape, for better or worse, the lived experience of patients who never met us and may never know our names.
That is why this work matters more than the boardroom conversations about it usually acknowledge. The vetting of an independent medical advisor is not a procurement exercise. It is a decision about whose judgement we are willing to place between our development strategy and the patients it will eventually serve.
We do not need advisors who are impressive on paper. We need advisors who have done the work, who carry the discipline of the specialty, and who remember, even on the difficult days of a programme that is behind and over budget, that the patients at the centre of it are the reason we are having this conversation at all.